JP2016525600A - シクロデキストリン - Google Patents

シクロデキストリン Download PDF

Info

Publication number
JP2016525600A
JP2016525600A JP2016526700A JP2016526700A JP2016525600A JP 2016525600 A JP2016525600 A JP 2016525600A JP 2016526700 A JP2016526700 A JP 2016526700A JP 2016526700 A JP2016526700 A JP 2016526700A JP 2016525600 A JP2016525600 A JP 2016525600A
Authority
JP
Japan
Prior art keywords
cyclodextrin
sbe
substitution
reaction
ether
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016526700A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016525600A5 (https=
Inventor
サベージ,タミー
ウィックス,ステファン
ミッチェル,ジョン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Curadev Pharma Pvt Ltd
Original Assignee
Curadev Pharma Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49081370&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2016525600(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Curadev Pharma Pvt Ltd filed Critical Curadev Pharma Pvt Ltd
Publication of JP2016525600A publication Critical patent/JP2016525600A/ja
Publication of JP2016525600A5 publication Critical patent/JP2016525600A5/ja
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/16Cyclodextrin; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2016526700A 2013-07-17 2014-07-16 シクロデキストリン Pending JP2016525600A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361847509P 2013-07-17 2013-07-17
GBGB1312737.8A GB201312737D0 (en) 2013-07-17 2013-07-17 Cyclodextrin
GB1312737.8 2013-07-17
US61/847,509 2013-07-17
PCT/GB2014/052173 WO2015008066A1 (en) 2013-07-17 2014-07-16 Cyclodextrin

Publications (2)

Publication Number Publication Date
JP2016525600A true JP2016525600A (ja) 2016-08-25
JP2016525600A5 JP2016525600A5 (https=) 2016-10-06

Family

ID=49081370

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016526700A Pending JP2016525600A (ja) 2013-07-17 2014-07-16 シクロデキストリン

Country Status (14)

Country Link
US (2) US11117978B2 (https=)
EP (1) EP3022231B1 (https=)
JP (1) JP2016525600A (https=)
KR (1) KR20160031019A (https=)
CN (1) CN105431458A (https=)
AP (1) AP2016008975A0 (https=)
AU (1) AU2014291800A1 (https=)
CA (1) CA2919501A1 (https=)
CL (1) CL2016000082A1 (https=)
GB (3) GB201312737D0 (https=)
HU (1) HUE038911T2 (https=)
MX (1) MX2016000553A (https=)
PT (1) PT3022231T (https=)
WO (1) WO2015008066A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10532102B2 (en) 2016-08-19 2020-01-14 Foresee Pharmaceuticals Co., Ltd. Pharmaceutical composition and methods of uses
WO2018140856A1 (en) 2017-01-30 2018-08-02 Bio-Rad Laboratories, Inc. Emulsion compositions and methods of their use
WO2018146698A1 (en) 2017-02-07 2018-08-16 Biophore India Pharmaceuticals Pvt. Ltd. Improved method for the preparation of sulfobutylether beta cyclodextrin sodium
CN112557541B (zh) * 2020-12-08 2022-07-12 河北科技大学 一种枸橼酸马罗匹坦及其有关物质的检测方法
CN112370451A (zh) * 2020-12-08 2021-02-19 河北科技大学 一种枸橼酸马罗匹坦包合物、注射液及制备方法
CN114369177A (zh) * 2021-12-31 2022-04-19 贵州省欣紫鸿药用辅料有限公司 一种采用管道反应器制备磺丁基醚-β-环糊精的方法
WO2025229196A1 (en) 2024-05-03 2025-11-06 Aalborg Universitet Primary side modified sulfoalkyl ether- and hydroxypropyl-cyclodextrins, synthesis and use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5874418A (en) 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
GB9713149D0 (en) 1997-06-21 1997-08-27 Pfizer Ltd Pharmaceutical formulations
ES2257795T3 (es) * 1997-07-01 2006-08-01 Pfizer Products Inc. Procedimiento para producir una ciclodextrina.
US6337380B1 (en) * 1998-12-01 2002-01-08 Fuji Photo Film Co., Ltd. Polymer having sulfonic acid group and silver halide photographic photosensitive material using the polymer
US6869939B2 (en) 2002-05-04 2005-03-22 Cydex, Inc. Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
CN100503647C (zh) 2005-11-02 2009-06-24 南京师范大学 羟丙基-磺丁基-β-环糊精及其制备方法、分析方法以及在药学上的应用
CN101686681B (zh) * 2007-04-27 2015-04-01 锡德克斯药物公司 包含氯吡格雷和磺基烷基醚环糊精的制剂和其使用方法
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
DK3702374T3 (da) * 2012-02-15 2022-06-27 Cydex Pharmaceuticals Inc Fremsgangsmåde til fremstilling for cyclodextrin-derivater
PH12012502259A1 (en) 2012-05-08 2019-07-03 Onyx Therapeutics Inc Cylodextrin complexation methods for formulating peptide proteasome inhibitors

Also Published As

Publication number Publication date
GB2519832A (en) 2015-05-06
GB201312737D0 (en) 2013-08-28
WO2015008066A1 (en) 2015-01-22
EP3022231B1 (en) 2018-04-18
AP2016008975A0 (en) 2016-01-31
GB2586104A (en) 2021-02-03
AU2014291800A1 (en) 2016-02-11
CN105431458A (zh) 2016-03-23
HUE038911T2 (hu) 2018-12-28
GB201412644D0 (en) 2014-08-27
US20160024229A1 (en) 2016-01-28
GB202015609D0 (en) 2020-11-18
US10239961B2 (en) 2019-03-26
MX2016000553A (es) 2016-08-01
US11117978B2 (en) 2021-09-14
GB2519832B (en) 2021-03-03
KR20160031019A (ko) 2016-03-21
US20150025023A1 (en) 2015-01-22
EP3022231A1 (en) 2016-05-25
CL2016000082A1 (es) 2016-09-23
CA2919501A1 (en) 2015-01-22
GB2586104B (en) 2021-03-31
PT3022231T (pt) 2018-06-11

Similar Documents

Publication Publication Date Title
JP2016525600A (ja) シクロデキストリン
Sarabia-Vallejo et al. Cyclodextrin inclusion complexes for improved drug bioavailability and activity: synthetic and analytical aspects
JP6508944B2 (ja) シクロデキストリン誘導体のための製造方法
Spiridon et al. Cyclodextrins as multifunctional platforms in drug delivery and beyond: structural features, functional applications, and future trends
Yuan et al. Evaluation of complex forming ability of hydroxypropyl-β-cyclodextrins
Adeoye et al. Cyclodextrin solubilization and complexation of antiretroviral drug lopinavir: In silico prediction; Effects of derivatization, molar ratio and preparation method
Kono et al. Elucidation of substituent distribution states for carboxymethyl chitosan by detailed NMR analysis
CN108778338A (zh) 活性药物成分的连续络合
Arshad et al. Microwave-assisted, sulfhydryl-modified β-cyclodextrin-silymarin inclusion complex: A diverse approach to improve oral drug bioavailability via enhanced mucoadhesion and permeation
Wang et al. Physicochemical properties and mechanism of solubilised neohesperidin system based on inclusion complex of hydroxypropyl-β-cyclodextrin
Nan et al. An economic, accessible and stable sulphated cyclodextrin polymer as selector for efficiently separating chiral drugs in HPLC
Tongiani et al. Sulfoalkyl ether-alkyl ether cyclodextrin derivatives, their synthesis, NMR characterization, and binding of 6α-methylprednisolone
Fürst et al. Mucoadhesive polymers: Design of S-protected thiolated cyclodextrin-based hydrogels
CN107574198B (zh) 一种采用醇沉分级制备螺旋糊精包结络合载体的方法
CN105143274A (zh) 糖原基水溶性增强剂
Volkova et al. Cyclodextrin effects on the distribution, solubility and transport properties of umifenovir
EP2736614B1 (en) Method of removing alkylene halogenohydrin from cellulose ether
Savage et al. Continuous tank reactor synthesis of highly substituted sulphobutylether β-cyclodextrins
Yudiarto et al. Separation of structural isomers using soluble β-cyclodextrin polymer by ultrafiltration
Savage et al. Cyclodextrin
Gorshkova et al. Water-soluble modified chitosan and its interaction with a polystyrenesulfonate anion
CN101224298B (zh) 一种丙泊酚组合物
US8865887B2 (en) Method for synthesizing calixarene and/or cyclodextrin copolymers, terpolymers and tetrapolymers, and uses thereof
CN101590029A (zh) 一种丙泊酚组合物
FR2954771A1 (fr) Nouveau procede de synthese de copolymeres, terpolymeres et tetrapolymeres de cyclodextrines et leurs utilisations

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160712